Q-omics provides the consensus-scored XKR8 profile across patient tissues and cancer cell-line models. XKR8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, XKR8 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, XKR8 RNA expression shows 18,769 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, BLCA, and UVM as cancer lineages where XKR8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XKR8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XKR8 survival associations across molecular data types. XKR8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XKR8 RNA expression–survival associations across cancer types. High XKR8 expression shows unfavorable associations in OV, LGG, LUSC, LIHC, MESO and CESC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify OV as the clearest survival context for XKR8 RNA expression.
This table summarizes XKR8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for XKR8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XKR8 shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, LUAD, HNSC and KIRC. The BLCA box plot shows higher XKR8 RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with XKR8 in patient tissues and cancer cell lines. In patient samples, XKR8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, XKR8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
